Join members of our Opto Plasma B Discovery 4.0 development team for a panel discussion about our latest antibody discovery workflow.
Robert Carnahan, PhD, and Seth Zost, PhD, from the Vanderbilt University Medical Center, describe how they have used the Beacon platform, to rapidly discover hundreds of unique antibodies against SARS-CoV-2.
Learn how we enable lead candidate down-selection in 1 day by performing functional characterization during primary screening. Case studies highlight how our customers are dramatically accelerating development of next-generation antibody therapeutics.
Find out how B Cell Antibody Discovery on the Beacon system can be used to rapidly screen human B cell to discover antibodies against difficult targets such as viruses.